Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Trelagliptin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 20/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.78 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.78 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.74 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trelagliptin SCHEMBL29349599 | 1.00 | DPP4 (1.00) | DPP4OPRM1OPRK1CYP1A2CYP3A4 | |
| Trelagliptin SCHEMBL175726 | 1.00 | DPP4 (1.00) | DPP4OPRM1OPRK1CYP1A2CYP3A4 | |
| Trelagliptin SCHEMBL878010 | 0.94 | DPP4 (1.00) | DPP4OPRM1OPRK1CYP1A2CYP3A4 | |
| Trelagliptin SCHEMBL4468875 | 0.94 | DPP4 (1.00) | DPP4OPRM1OPRK1CYP1A2CYP3A4 | |
| Trelagliptin SCHEMBL28390472 | 0.94 | DPP4 (1.00) | DPP4OPRM1OPRK1CYP1A2CYP3A4 | |
| Trelagliptin SCHEMBL29364762 | 0.94 | DPP4 (1.00) | DPP4OPRM1OPRK1CYP1A2CYP3A4 | |
| Trelagliptin SCHEMBL19534887 | 0.94 | DPP4 (1.00) | DPP4OPRM1OPRK1CYP1A2CYP3A4 | |
| SCHEMBL27964065 | 0.93 | DPP4 (0.86) | DPP4OPRM1OPRK1CYP1A2CYP3A4 | |
| SCHEMBL28151193 | 0.93 | DPP4 (0.86) | DPP4OPRM1OPRK1CYP1A2CYP3A4 | |
| SCHEMBL10331078 | 0.91 | DPP4 (0.84) | DPP4OPRM1OPRK1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 361 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250312456-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | BOEHRINGER INGELHEIM INT (DE) | 2025-10-09 | — | — | US | claimed |
| US-20220323434-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | BOEHRINGER INGELHEIM INT (DE) | 2022-10-13 | — | — | US | claimed |
| EP-3939577-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVE | Boehringer Ingelheim International GmbH (DE) | 2022-01-19 | — | — | EP | claimed |
| CN-112656945-A | Treatment of diabetes in patients unsuited for metformin therapy | 勃林格殷格翰国际有限公司 | 2021-04-16 | — | — | CN | claimed |
| US-20210093633-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | BOEHRINGER INGELHEIM INT (DE) | 2021-04-01 | — | — | US | claimed |
| US-10894787-B2 | Modulators of the GPR119 receptor and the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2021-01-19 | — | — | US | claimed |
| CN-102134229-B | Dipeptidyl peptidase inhibitors | 武田药品工业株式会社 | 2020-08-04 | — | — | CN | claimed |
| CN-102134231-B | Dipeptidyl peptidase inhibitors | 武田药品工业株式会社 | 2020-08-04 | — | — | CN | claimed |
| EP-3626238-A1 | DPP-4 INHIBITORS FOR USE FOR THE TREATMENT OF WOUND HEALING IN DIABETIC PATIENTS | Boehringer Ingelheim International GmbH (DE) | 2020-03-25 | — | — | EP | claimed |
| US-20190105321-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | BOEHRINGER INGELHEIM INT (DE) | 2019-04-11 | — | — | US | claimed |
| WO-2011005929-A1 | PIPERIDINE DERIVATIVE AND ITS USE FOR THE TREATMENT OF DIABETS AND OBESITY | ARENA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | WO | claimed |
| EP-2187879-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVE | Boehringer Ingelheim International GmbH (DE) | 2010-05-26 | — | — | EP | claimed |
| WO-2010018217-A2 | ORGANIC COMPOUNDS FOR WOUND HEALING | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-18 | — | — | WO | claimed |
| WO-2010015664-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-11 | — | — | WO | claimed |
| WO-2009147125-A1 | DPP-IV INHIBITORS FOR USE IN THE TREATMENT OF NAFLD | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-10 | — | — | WO | claimed |
| WO-2009022009-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A PYRAZOLE-O-GLUCOSIDE DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | WO | claimed |
| WO-2009022007-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | WO | claimed |
| EP-1586571-B1 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL (JP) | 2008-07-16 | — | — | EP | claimed |
| EP-1586571-A1 | Dipeptidyl peptidase inhibitors | Takeda San Diego, Inc. (US) | 2005-10-19 | — | — | EP | claimed |
| WO-2005095381-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-10-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210093633-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | DPP4, DPP3, DPP7 | DPP4 1/4885OPRM1 2436/4885OPRK1 3430/4885 |
| US-20250312456-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | DPP4, DPP3, DPP7 | DPP4 1/4885OPRM1 2436/4885OPRK1 3430/4885 |
| US-20220323434-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | DPP4, DPP3, DPP7 | DPP4 1/4885OPRM1 2436/4885OPRK1 3430/4885 |
| US-10894787-B2 | Modulators of the GPR119 receptor and the treatment of disorders related thereto | GPR119, GLP1R, DPP9 | DPP4 5/4885OPRM1 1209/4885OPRK1 1757/4885 |
| US-20190105321-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | DPP4, DPP3, DPP7 | DPP4 1/4885OPRM1 2436/4885OPRK1 3430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.